X4 Pharma cuts workforce 50%, saves ~$13M/yr; appoints new COO, execs depart

X4 Pharmaceuticals, Inc

Workforce reduction of ~50%, expected to generate ~$13M in annualized cost savings.
Cash charges of ~$3.3M for severance and termination-related costs; substantially complete in Q3 2025.
COO Mary DiBiase, CCO Mark Baldry, CLO Natasha Thoren terminated; CMO Christophe Arbet-Engels resigns.
John Volpone appointed COO in addition to his role as President; Executive Chairman Adam Craig oversees clinical development.
Restructuring aims to focus resources on completing the 4WARD Phase 3 trial for chronic neutropenia.

item 2.05item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.